Clinical Trial Update: AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of omacetaxine with standard induction therapy (cytarabine and idarubicin) in newly diagnosed acute myeloid leukemia; study terminated with post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Omacetaxine (omacetaxine mepesuccinate)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-06